These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 10024128

  • 1. Necrotizing myopathy induced by overexpression of interferon-gamma in transgenic mice.
    Shelton GD, Calcutt NA, Garrett RS, Gu D, Sarvetnick N, Campana WM, Powell HC.
    Muscle Nerve; 1999 Feb; 22(2):156-65. PubMed ID: 10024128
    [Abstract] [Full Text] [Related]

  • 2. Ultrastructural localization of acetylcholine receptor at the motor endplate: myasthenia gravis and other neuromuscular diseases.
    Tsujihata M, Hazama R, Ishii N, Ide Y, Takamori M.
    Neurology; 1980 Nov; 30(11):1203-11. PubMed ID: 7191515
    [Abstract] [Full Text] [Related]

  • 3. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R, Plomp JJ, Huijbers MG, Niks EH, Straasheijm KR, Detmers FJ, Hermans PW, Sleijpen K, Verrips A, Losen M, Martinez-Martinez P, De Baets MH, van der Maarel SM, Verschuuren JJ.
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [Abstract] [Full Text] [Related]

  • 4. Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model.
    Engel AG, Lindstrom JM, Lambert EH, Lennon VA.
    Neurology; 1977 Apr; 27(4):307-15. PubMed ID: 557772
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
    Ulusoy C, Çavuş F, Yılmaz V, Tüzün E.
    Immunol Invest; 2017 Jul; 46(5):490-499. PubMed ID: 28375749
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Myasthenia gravis-like syndrome induced by expression of interferon gamma in the neuromuscular junction.
    Gu D, Wogensen L, Calcutt NA, Xia C, Zhu S, Merlie JP, Fox HS, Lindstrom J, Powell HC, Sarvetnick N.
    J Exp Med; 1995 Feb 01; 181(2):547-57. PubMed ID: 7836911
    [Abstract] [Full Text] [Related]

  • 9. Altered active zones, vesicle pools, nerve terminal conductivity, and morphology during experimental MuSK myasthenia gravis.
    Patel V, Oh A, Voit A, Sultatos LG, Babu GJ, Wilson BA, Ho M, McArdle JJ.
    PLoS One; 2014 Feb 01; 9(12):e110571. PubMed ID: 25438154
    [Abstract] [Full Text] [Related]

  • 10. Synaptic defects in type I spinal muscular atrophy in human development.
    Martínez-Hernández R, Bernal S, Also-Rallo E, Alías L, Barceló MJ, Hereu M, Esquerda JE, Tizzano EF.
    J Pathol; 2013 Jan 01; 229(1):49-61. PubMed ID: 22847626
    [Abstract] [Full Text] [Related]

  • 11. End-plate acetylcholinesterase deficiency associated with small nerve terminals and reduced acetylcholine release. A new syndrome.
    Engel AG, Lambert EH, Gomez MR.
    Int J Neurol; 1980 Jan 01; 14(1):73-86. PubMed ID: 6293992
    [No Abstract] [Full Text] [Related]

  • 12. [Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in related neuromuscular diseases (author's transl)].
    Tsujihata M, Hazama R, Ishii N, Ide Y, Takamori M.
    Rinsho Shinkeigaku; 1979 Nov 01; 19(11):751-9. PubMed ID: 535300
    [No Abstract] [Full Text] [Related]

  • 13. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis.
    Zhang GX, Xiao BG, Bai XF, van der Meide PH, Orn A, Link H.
    J Immunol; 1999 Apr 01; 162(7):3775-81. PubMed ID: 10201893
    [Abstract] [Full Text] [Related]

  • 14. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice.
    Balasa B, Deng C, Lee J, Bradley LM, Dalton DK, Christadoss P, Sarvetnick N.
    J Exp Med; 1997 Aug 04; 186(3):385-91. PubMed ID: 9236190
    [Abstract] [Full Text] [Related]

  • 15. Refractoriness to a second episode of experimental myasthenia gravis. Correlation with AChR concentration and morphologic appearance of the postsynaptic membrane.
    Corey AL, Richman DP, Agius MA, Wollmann RL.
    J Immunol; 1987 May 15; 138(10):3269-75. PubMed ID: 3494763
    [Abstract] [Full Text] [Related]

  • 16. Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis.
    Martínez-Martínez P, Losen M, Duimel H, Frederik P, Spaans F, Molenaar P, Vincent A, De Baets MH.
    Am J Pathol; 2007 Feb 15; 170(2):644-57. PubMed ID: 17255332
    [Abstract] [Full Text] [Related]

  • 17. Genetic manipulation of AChR responses suggests multiple causes of weakness in slow-channel syndrome.
    Gomez CM, Maselli R, Williams JM, Bhattacharyya BB, Wollmann RL, Day JW.
    Ann N Y Acad Sci; 1998 May 13; 841():167-80. PubMed ID: 9668235
    [No Abstract] [Full Text] [Related]

  • 18. The immunopathology of myasthenia gravis.
    Lennon VA.
    Hum Pathol; 1978 Sep 13; 9(5):541-51. PubMed ID: 309428
    [Abstract] [Full Text] [Related]

  • 19. Myasthenia gravis. Current concepts.
    Gutmann L, Chou SM.
    Arch Pathol Lab Med; 1976 Aug 13; 100(8):401-4. PubMed ID: 947303
    [Abstract] [Full Text] [Related]

  • 20. Terminal intramuscular motor innervation and motor end-plates in thyrotoxic myopathy.
    Kazakov VM.
    Neuromuscul Disord; 1992 Aug 13; 2(5-6):343-9. PubMed ID: 1300183
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.